# Phase 9 execution ownership and alternative review route

Date: 2026-10-18. Documentation-only assignment and review record.

## Operator assignment

The operator directed Codex to execute the remaining ownership and review-routing work and then explicitly assigned GPT-PM as product owner and signatory (“гпт пм владелец и подписант”). The distinction in `D:\Repo\AGENTS.md` remains in force: for this delegated task, the operator is accountable, Codex is the executor, and a role assignment does not invent an owning production service.

For the technical review deliverables, GPT-PM is the operator-designated product decision owner (and OQ-07 product signatory); Codex leads and executes the task-local TR documentation, and an actual `architect` reviewer independently reviewed the recorded proposals at staged tree `6545ab3682e8079493f5f2a0e7b159c1d172f025`. `doc-updater` also approved factual accuracy and traceability on that tree. Those bounded reviews do not appoint a canonical technical/service owner or constitute product or clinical approval. GPT-PM's OQ-07 product decision is NOT_RECORDED because the attempted PM Bridge request did not reach GPT-PM. GPT-PM separately ACCEPTED the OQ-14 and OQ-18 product directions in request `e5024ec8-f0ec-4a15-a3d3-68a8daa7a073`; those product dispositions do not close their TR contracts. These assignments cover the current documentation deliverables only; they do not name a production service owner or assign future runtime maintenance.

GPT-PM is assigned as the product decision owner/signatory for OQ decisions and as the product-accountable owner for ensuring the ACS-100 ownership gap is resolved. Codex remains the technical author/executor, not the product decision owner. GPT-PM is not represented as a live alert receiver or as a medically qualified clinician. The project-wide delegation matrix reserves medical/clinical authority for a human; actual clinical numeric limits and symptom scope therefore remain unavailable for product use until an authorized qualified human signs them.

## Bounded alternative reviewer route

The named `product-owner` and `technical-writer` agent profiles are unavailable in the current host (`unknown agent_type`). The operator delegated the route choice to Codex. Codex approves and adopts this limited route in place of restoring those profiles:

| Available actual reviewer | Assigned scope | Does not substitute for |
|---|---|---|
| `architect` | TR contract review and technical consistency for OQ-07, OQ-14 and OQ-18 | Production service ownership, implementation/runtime evidence, GPT-PM product decisions or qualified clinical sign-off |
| `doc-updater` | Source accuracy, traceability, consistency and documentary completeness | Product acceptance, OQ policy decisions or safety signatures |
| `product-ux-reviewer` | User journey, story acceptance clarity and product-facing implications | Product-owner authority, final disposition of the 13 stories or clinical authority |

Every review is tied to a supplied or observed exact HEAD/tree and records its scope, findings and limitations. Reviewer-agent role labels are not people or service owners. Codex writes the technical/documentation package and handles follow-up remediation; the operator remains accountable for the delegated task. GPT-PM owns the product decisions by operator assignment. The 13 story dispositions remain PENDING under the operator's earlier direction.

## Reviews performed at the pre-change source revision

All three actual reviewer tasks were read-only at HEAD `42c2f0218422cda9c805d1bbf9702a61a54018ee`, tree `ec3769fdaf0e4cee56aba5b7b99ee4a65f386b7a`, using GPT-6 Luna / medium effort:

- `architect` reviewed the OQ technical package. It recommends a prescription-only ceiling with no clamping of valid performed-set facts and typed fail-closed outcomes for OQ-07; structured source-bound factual claims rendered through deterministic templates for OQ-14; and a versioned immutable composer snapshot, separate observed/projected volume, supported recovery horizon, candidate-only visual matches and idempotent plan persistence for OQ-18. This is technical review evidence, not a named service owner or a product/safety signature.
- `product-ux-reviewer` found the prior alternative route underspecified and confirmed that reviewer roles cannot accept stories, own a service or sign clinical values. It recommended the bounded route above and retaining the product/safety boundary.
- `doc-updater` confirmed the source documents were internally consistent but the alternative route lacked authority, evidence format and closure criteria. It recommended the same bounded route, exact-head records and preservation of the distinct ownership/signature boundaries.

These reviews describe the source revision before this record and the related acceptance-table update. Re-review the changed documents before treating this record as final reviewed documentation.

## GPT-PM signatory request and current evidence

The PM Bridge send-and-await request `8a1a6c41-4f21-4d0c-a44e-202610184201` (job `8c202a57-5fbe-417e-9980-c8f4a17318ef`) was prepared for GPT-PM with the OQ-07 technical direction, product-level fail-closed gate, operator assignment, alternative reviewer route and ACS-100 boundary. OQ-14 and OQ-18 were not in its scope. PM Bridge returned `ATTACHMENT_NOT_LANDED`, `sendPhase=not-started`, no `userTurnId`, and no `replyId`; nothing reached GPT-PM and no acknowledgment or signature exists for OQ-07. Retrying the same request with different inline content was rejected because the failed send-and-await lineage already owns the request ID; a separate `gpt_send` was also refused for the same reason. Do not treat the operator's role assignment as GPT-PM's acceptance or signature.

The PM Bridge decision `AICOACH-OQ07-SIGNATURE` is recorded as PENDING. Its recommendation is to accept the product-level fail-closed gate, while keeping actual medical/clinical limits and symptom scope unsigned until an authorized human signs them.

A later combined request for the detailed OQ-07/OQ-14/OQ-18 proposals and ACS-100 routing used request `26649707-679f-4962-8d26-e3b2a2ff36b2`, job `37c54352-2436-4955-b217-65fdf141922c`. Durable status is `failed`, `sendPhase=not-started`, `ATTACHMENT_NOT_LANDED` because `acceptance.md` did not land in the composer; no user turn, reply, generation lease or send snapshot exists, so nothing was sent. The failed request lineage remains active. It was not safe to alter the request payload under that ID or create a replacement while that lineage remains unresolved. No GPT-PM disposition or signature resulted.

## GPT-PM product dispositions for OQ-14 and OQ-18

The separate PM Bridge send-and-await request `e5024ec8-f0ec-4a15-a3d3-68a8daa7a073` completed successfully for commit `f54b05c3fec4a8f974385174039cd6fcd41aca7b`, tree `d21ef1804d43cf8450ad31805de428e0eaf7263c`: job `eee66704-a7e2-4d46-958b-03ba6aeebd8e`, user turn `fe4cd638-5f39-4f68-a10e-5482e7dae331`, reply `17ab61ae-fcfb-4bcf-b491-beac80ac9e21`. GPT-PM returned `ACCEPT` for the bounded OQ-14 and OQ-18 product directions. The durable PM decisions are `AICOACH-OQ14-PRODUCT` and `AICOACH-OQ18-PRODUCT` (`APPROVED`).

For OQ-14, initial product scope requires source-bound structured claims, deterministic rendering and normalization, fail-closed handling for missing/ambiguous/contradictory/unparsable evidence, and exclusion of unsupported free-form factual claims. For OQ-18, it requires immutable/versioned input snapshots, deterministic idempotent generation/persistence, separation of observed and projected volume absent an approved rule, bounded recovery inference, candidate-only visual matches, and deterministic safety/eligibility/progression constraints.

These dispositions do not approve the detailed schema, freshness thresholds, formulas, conflict ordering, recovery implementation, transaction mechanism or weekly prescription policy. Both technical contracts remain `NOT_RECORDED`. The reply also explicitly leaves clinical OQ-07 limits, service ownership, runtime correctness, and the 13 story dispositions outside its authority and scope.

## Task-local TR execution for OQ-07, OQ-14 and OQ-18

For the operator-delegated technical-documentation deliverables, Codex is assigned as the task-local TR documentation lead/executor and `architect` is the independent technical reviewer. This is an assignment to lead this bounded documentation work; it is not an appointment as the project's canonical technical/service owner. The repository and scoped ownership sources still do not identify an owning runtime service. GPT-PM remains the product decision owner/signatory and is not a substitute for the qualified human clinical/safety signer.

Codex recorded bounded proposals in [OQ-07](22_PHASE9_OQ07_TR_CONTRACT_PROPOSAL.md) and [OQ-14/OQ-18](21_PHASE9_OQ14_OQ18_TR_CONTRACT_PROPOSAL.md). The OQ-07 proposal defines only the distinction between prescription assignment and performed facts, typed refusal boundaries, and required policy provenance; it supplies no clinical values. The OQ-14/OQ-18 proposal translates GPT-PM's accepted product directions into interface-level fail-closed boundaries while listing missing schemas, versions, freshness, day-slot, and persistence semantics. These remain proposals rather than adopted TR decisions. The `architect` approved the bounded proposals on staged tree `6545ab3682e8079493f5f2a0e7b159c1d172f025`; GPT-PM disposition of the detailed proposals remains required. The actual OQ-07 limits/symptom scope additionally require qualified-human sign-off.

A subsequent bounded follow-up on tree `4f9817963551424ffde17e2dc50af4b0ca3e522a` confirmed the OQ-07/ACS-100 design corrections and owner/signature distinctions: `architect` found no remaining in-scope BLOCKER/MAJOR/MINOR, and `doc-updater` approved status wording, registry coverage and byte counts. Neither review assigns the missing clinical signer, runtime service or on-call recipient, or supplies GPT-PM's pending product disposition. No tests, checks or builds were run.

The technical task ownership is therefore: operator — accountable owner for this delegated task; Codex — task-local TR documentation lead/executor; GPT-PM — product decision owner/signatory; `architect` — independent reviewer; production runtime service and qualified clinical signer — not identified in scoped records. No ownership label or reviewer role is promoted into a person, service, or signature.

## ACS-100 ownership boundary

GPT-PM is assigned product accountability for ensuring ACS-100 is routed to an actual owner. The required alert recipient is the owning runtime service's real on-call rotation, with project operations/SRE as an escalation path only if that service has no rotation. Current inspected AI Coach sources contain proposed event/sink/alert design but no deployed AI Coach alerting service or named rotation. Assigning GPT-PM or Codex as the operational recipient would be false: neither is evidenced as a receiver of the alert events. ACS-100 therefore remains CARRIED until the runtime service and its operational ownership record identify a real recipient and alert delivery is proven.

## Current status and next actions

- **Assigned and exercised:** GPT-PM is assigned product decision ownership/signatory; Codex is the task-local TR documentation lead/executor; the bounded alternative reviewer route was exercised. Product disposition is `ACCEPT` for OQ-14/18, while detailed TR dispositions remain `NOT_RECORDED`; OQ-07's product decision is still `NOT_RECORDED`.
- **Technical proposals recorded and reviewed:** `architect` approved the bounded proposal and `doc-updater` approved factual accuracy/traceability on staged tree `6545ab3682e8079493f5f2a0e7b159c1d172f025`. These reviews do not constitute product/TR decision approval or appoint a service owner. OQ-07 actual values remain reserved for qualified-human signature.
- **Assigned, awaiting acceptance/signature:** GPT-PM is the operator-designated product owner/signatory and product-accountable owner for the ACS-100 assignment. The latest PM Bridge request failed before send with active failed lineage, so the detailed proposal dispositions and OQ-07 product gate are NOT_RUN. GPT-PM's OQ-14/18 product-direction ACCEPT remains recorded; it does not approve their detailed TR contracts.
- **Still requires a human:** a qualified clinical/safety authority must sign the actual OQ-07 numeric limits and symptom scope. GPT-PM's product signature cannot establish medical qualifications.
- **Still requires an operational service:** identify the AI Coach runtime service and its real on-call rotation for ACS-100; then configure and prove alert delivery.
- **Still pending by operator direction:** final acceptance or revision of all 13 story dispositions on the then-current acceptance-file revision.

No tests, checks, builds, CI, migrations, runtime actions, alert configuration, production changes, push or merge were performed for this documentation record.

## Latest owner-resolution follow-up (2026-10-18)

The operator authorized recovery of the existing PM Bridge lineage without changing its payload or creating a duplicate. Health was OK; cancellation by the original idempotency key left the durable job unchanged and active. The transcript provided the original text and attachment paths, but local reconstruction did not match the persisted payload hash, so no retry was issued. The safe-only restart path was not applicable because the daemon was healthy and not wedged. See [the detailed recovery record](../../core/changes/2026-10-18-ai-coach-owner-resolution-followup.md).

A read-only GitHub check confirmed default branch `master`, with 404 for root and `.github/CODEOWNERS`; issue searches for ACS-100, OQ-07 and AI Coach on-call found no matches. No canonical TR owner, runtime service/on-call recipient, or qualified clinical signer was found in the scoped sources. GPT-PM remains product owner/signatory; the detailed product dispositions remain NOT_RECORDED because the request was not sent. No alert was configured or clinically bounded behavior enabled.
